Marea Therapeutics, Inc., a clinical-stage biotechnology company, has announced its upcoming participation in the 93rd European Atherosclerosis Society (EAS) Congress, set to take place from May 4-7, 2025, in Glasgow, UK. The company will present two key studies, showcasing its cutting-edge research and advancements in cardioendocrine diseases, a field where they are pioneering innovative treatment approaches.

Founded with a focus on transforming the treatment of cardioendocrine diseases, Marea Therapeutics harnesses human genetics to design next-generation medicines. The company’s research aims to address unmet medical needs, particularly in metabolic dysfunction and cardiovascular diseases. Marea’s pipeline includes promising treatments targeting both cardiovascular and endocrine diseases, with its lead program, MAR001, currently in Phase 2 clinical development.

MAR001 is being evaluated for its efficacy in treating adults with metabolic dysfunction who are at high risk for cardiovascular disease. The company is also advancing MAR002, which is targeted at acromegaly, a rare disease caused by excess growth hormone. Marea’s research leverages cutting-edge gene therapy and molecular techniques to create treatments that aim to be more effective, safe, and sustainable than current therapies.

For more details please visit our website - https://www.medhealthinsight.com/marea-therapeutics-to-present-late-breaking-data-at-93rd-eas-congress/